CoChat

A placebo‐controlled screening trial of olanzapine, valproate, and coenzyme Q10/L‐carnitine for the treatment of cocaine dependence

Reid, Malcolm S., Casadonte, Paul, Baker, Sherryl, Sanfilipo, Michael, Braunstein, Dania, Hitzemann, Robert, Montgomery, Ann, Majewska, Dorota, Robinson, James, Rotrosen, John · 2005 · Addiction
Cited by 54

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Aims To conduct a medication screening trial on the efficacy of olanzapine, valproate or coenzyme Q10/L‐carnitine combination versus placebo for the treatment of cocaine dependence. Design A four‐arm, modified blinded, parallel group study in an out‐patient setting using the Cocaine Rapid Efficacy and Safety Trials (CREST) study design. Setting The study was performed at the New York Medications Development Research Unit (MDRU). Participants All participants met Diagnostic and Statistical Manual version IV (DSM‐IV) criteria for cocaine dependence and provided at least two urine samples positive for benzoylecgonine (BE) during the 2‐week screening period. Sixty‐eight participants were enrolled with 39 completing the study. Intervention After a 2‐week screening period, 68 subjects were assigned randomly to receive either olanzapine (10 mg/day), valproate (1500 mg/day), coenzyme Q10 (200 mg/day) and L‐carnitine (500 mg/day) combination or placebo for an 8‐week treatment period. All subjects also received individual cognitive behavioral counseling during treatment. Measurements Primary outcome measures included quantitative urine benzoylecgonine (BE) levels, self‐report of drug use, and global impression scores. Secondary outcomes included cocaine craving, study retention and related psychosocial measures. Safety measures included adverse event monitoring, vital signs, and extrapyramidal side‐effects tests. Results Study retention was similar across all treatment groups, and all groups showed improvement across most measures of treatment efficacy over the duration of the study. None of the study medications, however, were superior to placebo on any of the primary or secondary outcome measures. Cocaine use, as measured by urine BE levels and self‐report, was not significantly lower than placebo in any of the drug treatment groups. All study medications were equally well tolerated, and few medication side effects were observed. Conclusion This pilot study does not support the effectiveness of olanzapine, valproate or coenzyme Q10/ L‐carnitine combination for the treatment of cocaine dependence.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1360-0443.2005.00990.x

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 54

Metadata

Authors
Reid, M. S., Casadonte, P., Baker, S., Sanfilipo, M., Braunstein, D., Hitzemann, R., Montgomery, A., Majewska, D., Robinson, J., & Rotrosen, J.
Venue
Addiction
Publisher
Wiley
Published
2005-02-24
Volume
100
Issue
s1
Pages
43-57
ISSN
  • 0965-2140 (ISSN-L)
  • 1360-0443
OpenAlex
W2047453140
Cited by
54
References
6
FWCI
2.62
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A placebo‐controlled screening trial of olanzapine, valproate, and coenzyme Q10/L‐carnitine for the treatment of cocaine dependence. https://app.cochat.ai/papers/10.1111/j.1360-0443.2005.00990.x
The paper
Reid, M. S., Casadonte, P., Baker, S., Sanfilipo, M., Braunstein, D., Hitzemann, R., Montgomery, A., Majewska, D., Robinson, J., & Rotrosen, J. (2005). A placebo‐controlled screening trial of olanzapine, valproate, and coenzyme Q10/L‐carnitine for the treatment of cocaine dependence. Addiction. https://doi.org/10.1111/j.1360-0443.2005.00990.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.